Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Vaginal Diseases » Vaginitis
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Vaginal Diseases » Vaginitis
Description
Inflammation of the vagina characterized by pain and a purulent discharge. MeSH
Hierarchy View
Subtype Terms (4)
Atrophic Vaginitis
18 drugs (6 approved, 12 experimental)
Trichomonas Vaginitis
11 drugs (5 approved, 6 experimental)
Vaginosis, Bacterial
70 drugs (31 approved, 39 experimental)
Vulvovaginitis
10 drugs (8 approved, 2 experimental)
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (13)
Phase 2 Indicated Drugs (1)
Phase 1 Indicated Drugs (2)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (17)
Organization Involved with Phase 3 Indications (36)
Horizons Clinical Research Center, LLC
International Clinical Trials Association
Lawrence OB/GYN Clinical Research, LLC
Organization Involved with Phase 2 Indications (25)
Bill and Melinda Gates Foundation
Centers for Disease Control and Prevention (CDC)
Chiang Rai District Health Office
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (9)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
